Parkinson's disease-associated α-sylnuclein is more fibrillogenic than β- and γ-synuclein and cannot cross-seed its homologs

被引:152
作者
Biere, AL [1 ]
Wood, SJ [1 ]
Wypych, J [1 ]
Steavenson, S [1 ]
Jiang, YJ [1 ]
Anafi, D [1 ]
Jacobsen, FW [1 ]
Jarosinski, MA [1 ]
Wu, GM [1 ]
Louis, JC [1 ]
Martin, F [1 ]
Narhi, LO [1 ]
Citron, M [1 ]
机构
[1] Amgen Inc, Thousand Oaks, CA 91320 USA
关键词
D O I
10.1074/jbc.M005514200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Parkinson's disease (PD) is a neurodegenerative disorder that is pathologically characterized by the presence of intracytoplasmic Lewy bodies. Recently, two point mutations in alpha -synuclein were found to be associated with familial PD, but as of yet no mutations have been described in the homologous genes beta- and gamma -synuclein. alpha -Synuclein forms the major fibrillar component of Lewy bodies, but these do not stain for beta- or gamma -synuclein. This result is very surprising, given the extent of sequence conservation and the high similarity in expression and subcellular localization, in particular between alpha- and beta -synuclein, Here we compare in vitro fibrillogenesis of all three purified synucleins, We show that fresh solutions of alpha-, beta-, and gamma- synuclein show the same natively unfolded structure. While over time alpha -synuclein forms the previously described fibrils, no fibrils could be defected for beta- and gamma -synuclein under the same conditions. Most importantly, beta- and gamma -synuclein could not be cross-seeded with alpha -synuclein fibrils. How ever, under conditions that drastically accelerate aggregation, gamma -synuclein can form fibrils with a lag phase roughly three times longer than alpha -synuclein. These results indicate that beta- and gamma -synuclein are intrinsically less fibrillogenic than alpha -synuclein and cannot form mixed fibrils with alpha -synuclein, which mag explain why they do not appear in the pathological hallmarks of PD, although they are closely related to alpha -synuclein and are also abundant in brain.
引用
收藏
页码:34574 / 34579
页数:6
相关论文
共 36 条
[1]  
ANDREU JM, 1986, METHOD ENZYMOL, V130, P47
[2]   Argyrophilic glial inclusions in the midbrain of patients with Parkinson's disease and diffuse Lewy body disease are immunopositive for NACP/α-synuclein [J].
Arai, T ;
Uéda, K ;
Ikeda, K ;
Akiyama, H ;
Haga, C ;
Kondo, H ;
Kuroki, N ;
Niizato, K ;
Iritani, S ;
Tsuchiya, K .
NEUROSCIENCE LETTERS, 1999, 259 (02) :83-86
[3]   NACP/α-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy [J].
Arima, K ;
Uéda, K ;
Sunohara, N ;
Arakawa, K ;
Hirai, S ;
Nakamura, M ;
Tonozuka-Uehara, H ;
Kawai, M .
ACTA NEUROPATHOLOGICA, 1998, 96 (05) :439-444
[4]  
Baba M, 1998, AM J PATHOL, V152, P879
[5]   EMPIRICAL PREDICTIONS OF PROTEIN CONFORMATION [J].
CHOU, PY ;
FASMAN, GD .
ANNUAL REVIEW OF BIOCHEMISTRY, 1978, 47 :251-276
[6]   The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease [J].
Clayton, DF ;
George, JM .
TRENDS IN NEUROSCIENCES, 1998, 21 (06) :249-254
[7]   Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease:: Implications for pathogenesis and therapy [J].
Conway, KA ;
Lee, SJ ;
Rochet, JC ;
Ding, TT ;
Williamson, RE ;
Lansbury, PT .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (02) :571-576
[8]   Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease [J].
Conway, KA ;
Harper, JD ;
Lansbury, PT .
NATURE MEDICINE, 1998, 4 (11) :1318-1320
[9]   PROTEIN SECONDARY STRUCTURES IN WATER FROM 2ND-DERIVATIVE AMIDE-I INFRARED-SPECTRA [J].
DONG, A ;
HUANG, P ;
CAUGHEY, WS .
BIOCHEMISTRY, 1990, 29 (13) :3303-3308
[10]   INFRARED SPECTROSCOPIC STUDIES OF LYOPHILIZATION-INDUCED AND TEMPERATURE-INDUCED PROTEIN AGGREGATION [J].
DONG, AC ;
PRESTRELSKI, SJ ;
ALLISON, SD ;
CARPENTER, JF .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1995, 84 (04) :415-424